<DOC>
	<DOC>NCT01233739</DOC>
	<brief_summary>Patients who present rhizarthrosis diagnostic will be randomized to be treated with chondroitin sulfate or placebo during 24 weeks to study the effect of the treatment with objective and subjective indicators of pain and sensibility.</brief_summary>
	<brief_title>Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis.</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>both sex patients age between 45 to 75 years with mechanical pain at the trapeziumthumb metacarpal joint of more than 3 months duration grade II or III Eaton &amp; Glickel rhizarthrosis radiological diagnose pain at inclusion of &gt;= 40 mm at a visual analogue scale without rehabilitation treatment or infiltration in the last 6 months who accept to participate and sign informed consent patients with rhizarthrosis resulted from rheumatic disease patients with joint surgery or traumatic background illiterate patients or unable to understand informed consent patients with previous neuropsychopathology enough severe to unable participation at the study patients with peripheral sensory impairment due to diabetes, peripheral neuropathy or central neurological sequelae of disease in the affected limb that can alter sensory perception patients with coagulopathy inflammation for other process at the joint at study in treatment with nonsteroidal antiinflammatory drug in the last 7 days and/or corticosteroid in the last 30 days allergy or hypersensibility at chondroitin sulfate or its excipients pregnant or breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>rhizarthrosis</keyword>
	<keyword>Chondroitin sulfate</keyword>
	<keyword>Placebo</keyword>
</DOC>